Pfizer Inks $325 Million Deal to Exit Neurontin Class Action

, The Litigation Daily


After a failed bid by Quinn Emanuel for help from the U.S. Supreme Court, Pfizer opted to settle claims over the company's marketing of its epilepsy drug.

What's being said

Comments are not moderated. To report offensive comments, click here.

Preparing comment abuse report for Article# 1202657671887

Thank you!

This article's comments will be reviewed.